WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer reports first-quarter 2012 results 01 May 2012
Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents 12 March 2012
Pfizer acquires Alacer Corp., a leading vitamin supplements company 28 February 2012
Pfizer and Hisun announce progress on potential joint venture 20 February 2012
Pfizer reports fourth-quarter and full-year 2011 results 31 January 2012
Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care 29 January 2012
Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon 17 January 2012
A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health 10 January 2012
Pfizer Receives FDA Approval to Extend Use of Prevnar 13® 01 January 2012
Prevent Pneumococcal Disease in Infants and Young Children in the World's Poorest Countries 18 December 2011
Pfizer Elects CEO Ian Read as Chairman of the Board 12 December 2011
Pfizer Completes Acquisition of Excaliard 04 December 2011
Pfizer to Acquire Excaliard Pharmaceuticals 22 November 2011
Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program 20 November 2011
Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits 07 November 2011
Pfizer Reports Third-Quarter 2011 Results 01 November 2011
Pfizer Completes Acquisition Of Icagen 30 October 2011
Humana and Pfizer Form Research Partnership 13 October 2011
Pfizer Announces Licensing Agreement With Puma Biotechnology 06 October 2011
NABP and Pfizer Partner to Educate Patients About The Flood of Counterfeit Medicines Online 30 September 2011
  • Start
  • Prev
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.